Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810509 | 0.85 | CBFB (0.41) | — | |
| SCHEMBL2809880 | 0.85 | PDE4A (0.39) | PDE4APDE4DPDE3BPDE3AWDR5 | |
| SCHEMBL20772800 | 0.81 | CHRNB4 (0.42) | PDE4APDE4DPDE3BPDE3APARP15 | |
| SCHEMBL8263863 | 0.80 | ALDH1A1 (0.41) | CNR1CNR2 | |
| SCHEMBL2809960 | 0.78 | ACHE (0.47) | F2EP300PARP15PARP10PARP2 | |
| SCHEMBL16396441 | 0.76 | PIM1 (0.40) | F2EP300PARP15PARP10PARP2 | |
| SCHEMBL2807883 | 0.76 | ACHE (0.48) | CNR1CNR2 | |
| SCHEMBL3134747 | 0.76 | DAO (0.39) | PDE4DCNR1CNR2 | |
| SCHEMBL10068795 | 0.75 | WDR5 (0.44) | PDE4APDE4DF2WDR5PARP15 | |
| SCHEMBL22964248 | 0.75 | HTR6 (0.39) | PDE4APDE4DCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2081894-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SmithKline Beecham Corporation (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | PPARD, PPARA, PPARG | PDE4A 736/4885PDE4D 1043/4885PDE3B 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.